Sutro biopharma, inc. (STRO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
Revenues (including amounts from related parties of $2,813 during the three months ended March 31, 2020, and $4,916 during the three months ended March 31, 2019)

42,736

38,419

51,741

-

Total revenue

-

-

-

59,731

Operating expenses
Research and development

65,612

54,262

54,639

43,550

General and administrative

32,592

21,380

16,374

14,817

Total operating expenses

98,204

75,642

71,013

58,367

Loss from operations

-55,468

-37,223

-19,272

1,364

Interest income

4,074

1,616

273

251

Interest and other income (expense), net

-4,350

290

-689

-

Interest expense

-

-

-

0

Other income (expense), net

-

-

-

87

Net loss

-55,744

-35,317

-19,688

1,702

Net loss per share

-2.43

-6.13

-43.95

0.00

Weighted-average shares used in computing net loss per share

22,958

5,758

447

407

Collaboration Revenue
Total revenue

-

-

-

59,731

Other Revenue
Total revenue

-

-

-

0